SHP-2 increases β-catenin accumulation by inhibiting glycogen synthase kinase 3β (GSK3β)-mediated β-catenin degradation in liver cancer stem cells to enhance the self-renewal of liver cancer stem cells. Here, PTPN11 is linked to liver cancer.